-
1.发明申请Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators 有权包含CBx大麻素受体调节剂和钾通道调节剂的药物组合物公开(公告)号：US20070254862A1
公开(公告)日：2007-11-01
申请号：US11796716
申请日：2007-04-26
IPC分类号： A61K31/5377 , A61K31/55 , A61K31/535 , A61K31/454 , A61K31/4152 , A61K31/397 , A61K31/396
CPC分类号： A61K31/535 , A61K31/396 , A61K31/397 , A61K31/4152 , A61K31/454 , A61K31/5377 , A61K31/55 , A61K45/06 , Y10S514/866 , A61K2300/00
摘要： Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a KATP channel modulator; and (ii) a CBx modulator. Also described herein are methods of making and using these compositions.
摘要翻译： 本文描述的是包含治疗有效量的（i）K ATP通道调节剂的药物组合物; 和（ii）CB
调制器。 本文还描述了制备和使用这些组合物的方法。 -
2.发明申请Use of CBx cannabinoid receptor modulators as potassium channel modulators 审中-公开使用CBx大麻素受体调节剂作为钾通道调节剂公开(公告)号：US20070254863A1
公开(公告)日：2007-11-01
申请号：US11796740
申请日：2007-04-26
IPC分类号： A61K31/55 , A61K31/5377 , A61K31/454
CPC分类号： A61K31/454 , A61K31/5377 , A61K31/55
摘要： Methods of treating one or more medical conditions by administering to a subject in need thereof an effective amount of a CBx modulator having KATP channel modulating properties are described herein. Also described are methods of using a CBx modulator having KATP channel modulating properties to treat one or more medical conditions.
摘要翻译： 本文描述了通过向有需要的受试者施用有效量的具有K ATP通道调节特性的CB调节剂来治疗一种或多种医学病症的方法。 还描述了使用具有K + ATP通道调节性质的CB调节剂治疗一种或多种医学病症的方法。
-
3.发明申请Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions 审中-公开含有N-氨磺酰基-N'-芳基哌嗪的药物组合物用于治疗或抑制肥胖症及相关病症公开(公告)号：US20050261292A1
公开(公告)日：2005-11-24
申请号：US11130268
申请日：2005-05-17
申请人： Jochen Antel , Michael Firnges , Peter-Colin Gregory , Uwe Reinecker , Uwe Schoen , Harald Waldeck , Michael Wurl , Dania Reiche
发明人： Jochen Antel , Michael Firnges , Peter-Colin Gregory , Uwe Reinecker , Uwe Schoen , Harald Waldeck , Michael Wurl , Dania Reiche
IPC分类号： A61K31/496 , A61K31/497 , A61K31/501 , A61K31/519 , A61K31/53 , C07D213/74 , C07D295/26 , C07D43/02
CPC分类号： A61K31/496 , A61K31/497 , A61K31/501 , A61K31/519 , A61K31/53 , C07D213/74 , C07D295/26
摘要： The present invention relates to the use of known and novel N-sulfamoyl-N′-arylpiperazines corresponding to Formula I and their physiologically compatible acid addition salts for the treatment or inhibition of obesity and related conditions.
摘要翻译： 本发明涉及对应于式I的已知和新型N-氨磺酰基-N'-芳基哌嗪及其生理相容的酸加成盐在治疗或抑制肥胖症及相关病症中的用途。
-
公开(公告)号：US20070191357A1
公开(公告)日：2007-08-16
申请号：US11465258
申请日：2006-08-17
IPC分类号： A61K31/425
CPC分类号： A61K31/425 , A61K31/085 , A61K31/415 , A61K31/4155 , A61K31/4439 , A61K31/5383 , A61K31/549 , A61K45/06 , A61K2300/00
摘要： Described herein are methods of treating, preventing or inhibiting a variety of medical conditions by administering to subjects in need thereof an effective amount of at least one potassium Kv1.3 channel inhibiting compound which can optionally also have either or both CBx modulating properties and/or potassium K(atp) channel opening properties. Also described is the use of potassium Kv1.3 channel inhibiting compounds in a pharmaceutical composition for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of a variety of medical conditions.
摘要翻译： 本文描述的是通过向有需要的受试者施用有效量的至少一种钾K1-3.3通道抑制化合物来治疗，预防或抑制多种医学病症的方法，其可任选地还可以具有 或两个CB x调制性质和/或钾（atp）通道开口性质。 还描述了在药物组合物中用于预防，治疗，延迟进展，延迟发作和/或抑制各种医学病症的钾通道抑制化合物的用途。
-
5.发明授权N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions 有权N-氨磺酰基 - 哌啶酰胺，用于治疗或抑制肥胖症和相关病症公开(公告)号：US07772225B2
公开(公告)日：2010-08-10
申请号：US11635514
申请日：2006-12-08
申请人： Jochen Antel , Michael Firnges , Uwe Schoen , Harald Waldeck , Michael Wurl , Dania Reiche , Peter-Colin Gregory
发明人： Jochen Antel , Michael Firnges , Uwe Schoen , Harald Waldeck , Michael Wurl , Dania Reiche , Peter-Colin Gregory
IPC分类号： A01N43/00 , A01N43/58 , A01N43/40 , A61K31/55 , A61K31/54 , A61K31/535 , A61K31/50 , A61K31/497 , A61K31/445 , C07D223/14 , C07D279/12 , C07D295/00 , C07D265/28 , C07D239/00 , C07D239/70 , C07D471/00 , C07D487/00 , C07D241/04 , C07D211/00
CPC分类号： C07D211/96 , C07D401/04 , C07D401/12 , C07D409/12 , C07D413/04
摘要： The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions.
摘要翻译： 本发明涉及式I的新型N-氨磺酰 - 哌啶酰胺及其生理上可接受的酸加成盐，包括它们的药物组合物，其制备方法及其用于治疗肥胖及其伴随和/或继发性疾病的用途，以及 相关或其他条件。
-
公开(公告)号：US07547708B2
公开(公告)日：2009-06-16
申请号：US11598684
申请日：2006-11-14
申请人： Jochen Antel , Harald Waldeck , Uwe Schoen , Peter-Colin Gregory , Michael Wurl , Michael Firnges , Dania Reiche , Uwe Reinecker , Holger Sann
发明人： Jochen Antel , Harald Waldeck , Uwe Schoen , Peter-Colin Gregory , Michael Wurl , Michael Firnges , Dania Reiche , Uwe Reinecker , Holger Sann
IPC分类号： A61K31/438 , C07D491/10
CPC分类号： C07D491/10
摘要： N-sulfamoyl-N′-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions
摘要翻译： 式I的N-氨磺酰基-N'-苯并吡喃哌啶化合物及其生理上可接受的酸加成盐，包含它们的药物组合物，其制备方法及其用于治疗和/或抑制青光眼，癫痫，双相性精神障碍，偏头痛， 神经性疼痛，肥胖症，II型糖尿病，代谢综合征，酒精依赖性和/或癌症，以及相关并发症和/或继发性疾病或病症
-
7.发明授权Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators 有权包含CBx大麻素受体调节剂和钾通道调节剂的药物组合物公开(公告)号：US07763607B2
公开(公告)日：2010-07-27
申请号：US11796716
申请日：2007-04-26
申请人： Jochen Antel , Peter-Colin Gregory , Josephus Hubertus Maria Lange , Michael Firnges , Dania Reiche
发明人： Jochen Antel , Peter-Colin Gregory , Josephus Hubertus Maria Lange , Michael Firnges , Dania Reiche
IPC分类号： A61K31/54 , A61K31/44 , A61K31/425
CPC分类号： A61K31/535 , A61K31/396 , A61K31/397 , A61K31/4152 , A61K31/454 , A61K31/5377 , A61K31/55 , A61K45/06 , Y10S514/866 , A61K2300/00
摘要： Described herein are pharmaceutical compositions comprising therapeutically effective quantities of (i) a KATP channel modulator; and (ii) a CBx modulator. Also described herein are methods of making and using these compositions.
摘要翻译： 本文描述的是药物组合物，其包含治疗有效量的（i）KATP通道调节剂; 和（ii）CBx调节剂。 本文还描述了制备和使用这些组合物的方法。
-
8.发明申请N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions 有权N-磺酰胺 - 哌啶酰胺，用于治疗或抑制肥胖症和相关病症公开(公告)号：US20070149512A1
公开(公告)日：2007-06-28
申请号：US11635514
申请日：2006-12-08
申请人： Jochen Antel , Michael Firnges , Uwe Schoen , Harald Waldeck , Michael Wurl , Dania Reiche , Peter-Colin Gregory
发明人： Jochen Antel , Michael Firnges , Uwe Schoen , Harald Waldeck , Michael Wurl , Dania Reiche , Peter-Colin Gregory
IPC分类号： A61K31/541 , A61K31/5377 , A61K31/496 , A61K31/454 , C07D401/02 , C07D413/02 , C07D417/02
CPC分类号： C07D211/96 , C07D401/04 , C07D401/12 , C07D409/12 , C07D413/04
摘要： The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions.
摘要翻译： 本发明涉及式I的新型N-氨磺酰 - 哌啶酰胺及其生理上可接受的酸加成盐，包括它们的药物组合物，其制备方法及其用于治疗肥胖及其伴随和/或继发性疾病的用途，以及 相关或其他条件。
-
公开(公告)号：US20070117823A1
公开(公告)日：2007-05-24
申请号：US11598684
申请日：2006-11-14
申请人： Jochen Antel , Harald Waldeck , Uwe Schoen , Peter-Colin Gregory , Michael Wurl , Michael Firnges , Dania Reiche , Uwe Reinecker
发明人： Jochen Antel , Harald Waldeck , Uwe Schoen , Peter-Colin Gregory , Michael Wurl , Michael Firnges , Dania Reiche , Uwe Reinecker
IPC分类号： A61K31/4747 , C07D491/10
CPC分类号： C07D491/10
摘要： N-sulfamoyl-N′-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions.
摘要翻译： 式I的N-氨磺酰基-N'-苯并吡喃哌啶化合物及其生理上可接受的酸加成盐，包含它们的药物组合物，其制备方法及其用于治疗和/或抑制青光眼，癫痫，双相性精神障碍，偏头痛， 神经性疼痛，肥胖症，II型糖尿病，代谢综合征，酒精依赖性和/或癌症，以及相关并发症和/或继发性疾病或病症。
-
10.发明授权公开(公告)号：US07592344B2
公开(公告)日：2009-09-22
申请号：US11606337
申请日：2006-11-30
申请人： Jochen Antel , Daniel Jasserand , Uwe Schoen , Michael Firnges , Holger Sann , Reinhard Brueckner , Dania Reiche
发明人： Jochen Antel , Daniel Jasserand , Uwe Schoen , Michael Firnges , Holger Sann , Reinhard Brueckner , Dania Reiche
IPC分类号： A61K31/496
CPC分类号： C07D405/06 , C07D295/155 , C07D307/54 , C07D307/84 , C07D317/60 , C07D333/24 , C07D333/60 , C07D407/06 , C07D409/06
摘要： 3-cyanonaphthalene-1-carboxylic acid perhydroxyalkylmethyl-piperazine compounds of formula I which are antagonistic to tachykinin receptors, pharmaceutical compositions containing such compounds, methods of using such compounds for the treatment and/or inhibition of various diseases and disorders, processes for preparing such piperazine compounds, and intermediate products of these processes.
摘要翻译： 拮抗速激肽受体的式I的3-氰基萘-1-羧酸全羟烷基甲基 - 哌嗪化合物，含有这些化合物的药物组合物，使用这些化合物治疗和/或抑制各种疾病和病症的方法，制备方法 哌嗪化合物和这些方法的中间产物。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.029 秒)
